Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 68-year-old male is evaluated in the outpatient clinic for new-onset muscle pain and weakness. He is currently on day 14 of a planned 28-day course of intravenous daptomycin for right-sided infective endocarditis caused by methicillin-resistant *Staphylococcus aureus* (MRSA). His medical history is significant for coronary artery disease and hyperlipidemia, for which he takes aspirin, metoprolol, and rosuvastatin. The patient states that the muscle aches began three days ago, primarily affecting his bilateral thighs and shoulders, making it difficult to stand up from a seated position. His temperature is 37.1°C (98.8°F), blood pressure is 132/84 mmHg, and pulse is 76/min. Physical examination reveals symmetrical muscle tenderness to palpation in the proximal upper and lower extremities. Sensation and deep tendon reflexes are intact. Which of the following is the most appropriate next step in the management of this patient?

  1. A
    Switch rosuvastatin to gemfibrozil and schedule a follow-up appointment in one week
  2. B
    Obtain an erythrocyte sedimentation rate and initiate empiric therapy with oral prednisone
  3. Discontinue daptomycin and rosuvastatin, and obtain a serum creatine phosphokinase levelCevap
  4. D
    Order bilateral lower extremity venous duplex ultrasonography
  5. E
    Consult neurology for nerve conduction studies and electromyography

Cevap

The most appropriate next step is discontinuing the offending agents (daptomycin and rosuvastatin) and measuring serum creatine phosphokinase (CPK) levels.
The correct action involves immediately stopping both myotoxic drugs and obtaining a serum creatine phosphokinase (CPK) level. Daptomycin is an active lipopeptide antibiotic known to cause skeletal muscle toxicity. Current guidelines mandate baseline and at least weekly CPK monitoring for all patients on daptomycin. The risk of myopathy and rhabdomyolysis is substantially increased when daptomycin is coadministered with HMG-CoA reductase inhibitors (statins). Given this patient's symptomatic presentation (proximal muscle pain, weakness, and tenderness), the most urgent action is ceasing the offending agents and quantifying muscle breakdown via CPK to guide further management.

Adım Adım Çözüm

1
Evaluate the clinical presentation alongside the patient's active medication list.
Identified symmetric proximal muscle pain and weakness in a patient concurrently taking intravenous daptomycin and a statin.
Both daptomycin and HMG-CoA reductase inhibitors independently carry a significant risk of skeletal muscle toxicity.
2
Determine the necessary therapeutic intervention to prevent further patient harm.
Decision made to immediately halt both daptomycin and rosuvastatin.
Continuing these myotoxic agents in a symptomatic patient can rapidly lead to severe rhabdomyolysis and acute kidney injury.
3
Select the appropriate diagnostic surveillance test to quantify the adverse event.
A serum creatine phosphokinase (CPK) level is ordered.
CPK is the definitive biomarker for skeletal muscle breakdown and is the gold standard for monitoring daptomycin-induced myopathy.

Anahtar Kavram

Patients receiving daptomycin require at least weekly monitoring of serum creatine phosphokinase (CPK). If a patient develops symptomatic myopathy, daptomycin and any other concurrently administered myotoxic drugs (such as statins) must be immediately discontinued and a CPK level obtained.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru